X4 Pharmaceuticals

Patient commitment is at the very core of X4.?? ? We work with grit and tenacity to create a future that patients deserve – through our medicines and by advocating for the needs of the primary immunodeficiency community. Today we unveil Rare Resolve, a reflection of our unwavering dedication to providing solutions to patients living with rare immune disorders.?? ?? Our passion for patients is what we take most pride in, and we look forward to the potential of impacting more patients around the world. Learn about our Rare Resolve: https://www.x4pharma.com ? #RareResolve #RareDiseaseDay #rarediseases #WHIMsyndrome #chronicneutropenia #immunodeficiencies

Our Chief Financial Officer, Adam Mostafa, recently participated in a Life Science Accounting & Reporting CFO Leadership Panel focused on ensuring positive culture, responding to market challenges, and navigating focus. #LifeSciences #CFO #Finance "I believe financing the life sciences industry requires a flexibility not seen in other industries. At X4, our creativity and grit have allowed us to adapt our financial strategy over time to overcome challenges in rare disease drug development, the changing regulatory landscape, and macro-economic factors to successfully support our first drug approval and launch in 2024."

We will report fourth-quarter and full-year 2024 financial results and host a conference call and webcast on March 25, 2025. More in today’s release: https://bit.ly/41HN2M2

Today we celebrate International Women’s Day and the women at X4 who are committed to driving progress for people living with rare immune disorders, including our CEO Paula Ragan, Ph.D. She recently spoke at Goodwin’s Rare Disease Symposium to share her perspective as CEO of a biotech committed to rare diseases, her path to founding X4 and our industry’s responsibility to not leave any patient behind. Watch the discussion here: https://bit.ly/4gVLZxQ #IWD2025 #immunodeficiency #primaryimmunodeficiency #WHIMsyndrome #chronicneutropenia

X4 is here at the 2025 American Academy of Allergy, Asthma and Immunology - AAAAI Congress. We are proud to share our mission of raising awareness of #WHIMsyndrome — a distinct, diagnosable, and treatable combined primary #immunodeficiency. Explore our interactive station at Booth 815 to learn more about the underlying cause of WHIM syndrome, CXCR4 pathway dysregulation. #AAAAI25 #RareDiseaseDay #immunology #raredisease

Jorey Berry, president and CEO of the?Immune Deficiency Foundation, spoke with the X4 team to honor Rare Disease Day and our shared dedication to people living with primary immunodeficiencies. Jorey emphasized the?organization's?mission to meet the needs of this community by working with patients, family members and leading immunologists to help understand the experience of living with a rare immune disorder. ? We thank Jorey and the?Immune Deficiency Foundation?for their role in increasing funds, resources and awareness of conditions like WHIM syndrome and chronic neutropenia, and look forward to continuing to support their mission. Learn more about?IDF:?https://primaryimmune.org/ ? #RareDiseaseDay #rarediseases #WHIMsyndrome #chronicneutropenia #primaryimmunodeficiency #PIcommunity

WHIM syndrome is a rare, treatable combined primary immunodeficiency and chronic neutropenic disorder with a clinical presentation that can be heterogeneous, nonspecific, and variable over time. These characteristics can contribute to diagnostic delays and long-term complications, including irreversible organ damage. Explore profiles based on real patient cases designed to help you recognize WHIM syndrome in your practice and take the next step in making a timely diagnosis. ? View patient profiles and other diagnostic tools at: https://bit.ly/4gL0mVK #AAAAI25 #raredisease #WHIMsyndrome #immunology #immunodeficiency

Have you or a loved one been diagnosed with #WHIMsyndrome? Our nurse educator is available to provide support and education on this rare #immunodeficiency. To learn more about how to navigate this rare #immunodeficiency from a specialist, contact [email protected].

Today we announced a collaboration with taiba rare to commercialize #mavorixafor in select Middle East countries for the treatment of WHIM syndrome. taiba rare is a leading specialty and orphan drug marketing, sales, and distribution company in the Middle East and North Africa. We look forward to working with them to further expand the global reach of mavorixafor. Read about the partnership in our latest release: https://lnkd.in/e2HP-xqB #partnership #immunodeficiency #primaryimmunodeficiency #raredisease #biotechpartner #RareDiseaseDay

CEO Paula Ragan, Ph.D.?spoke to CheckRare about the potential to extend our impact to more patients living with WHIM syndrome globally, beginning with our EMA MAA validation and exclusive licensing and supply agreement with Norgine. Paula discussed our ambition to deliver new treatment options to patients with immunodeficiencies, building off our FDA approval last year.?? ? Watch the interview here:?https://bit.ly/3WSIQYy? ? #WHIMsyndrome #RareDiseaseDay #immunodeficiencies #MAAvalidation #RareDisease?